“This increase in drug-related deaths was thought to be driven by a combination of numerous factors, including an increasingly volatile unregulated drug supply, barriers to accessing harm reduction services and treatment, and physical distancing requirements leading to more people using drugs alone”
Understanding the circumstances that contribute to these deaths is urgently needed to inform interventions and policies to prevent opioid-related mortality in the midst of the COVID-19 pandemic.
Without access to harm reduction, PWUD are potentially at greater risk of acquiring blood-borne viruses
Pandemic response measures such as physical distancing and social isolation have disrupted the healthcare and support services that people who use or have used substances and their communities typically rely on.
Preliminary data regarding SSP operational and service delivery changes during the US’ response to the COVID-19 global pandemic and provide key policy and service provision im- plications for SSPs.
COVID-19 pandemic compounds an ongoing public health crisis. There is a heightened need to reduce avoidable pressures on healthcare systems and support people who use opioids.
Given the persistent opioid mortality crisis especially in North America, the time has come to move towards providing risk population-wide SOD as an essential public health intervention
Targeting people who use drugs has not only a negative impact on individuals, but their families and broader society
Measures implemented to prevent the spread of COVID-19 are having a mixed impact on the drug supply chain